A first patient with primary liver cancer has been treated with a technology invented at the CHUV and licensed to Biocompatibles by the PACTT

In August 2015, PACTT was pleased to announce the signature of a license agreement and a development collaboration between CHUV and Biocompatibles International plc, part of the specialist healthcare company BTG plc, for a technology developed by Professor Alban Denys at the Radiodiagnostic and Interventional Radiology Unit at the CHUV. The technology enables the treatment of liver cancer using X-ray imageable microscopic beads loaded with a targeted anti-cancer drug placed directly in the liver

The UCL Cancer Institute and BTG plc have now begun to enroll patients into the first clinical trial. For Professor Denys “it is a great satisfaction to see this technology now entering the clinical stage, providing patients with liver cancer hope for additional treatment options.”

Tor read the complete presse relase, please click here.

For BTG website, please click here.


Back to news list